Copenhagen, Denmark, 6 May 2022 – FluoGuide A/S (“FluoGuide” or the “Company”) invites to a presentation of the results from the clinical trial of FG001 used to guide surgery in patients with aggressive high-grade glioma brain cancer, which will first be presented at the 68th Scandinavian Neurosurgical Society (SNS) Congress held 14-16 May 2022, in Bergen, Norway
As a follow-up on the presentation done by Principal Investigator and Chief Surgeon Jane Skjøth-Rasmussen in Bergen, FluoGuide hereby invites to an online presentation of the same data that will be presented at the SNS congress.
Resume of the trial:
In total, 40 patients have been administered FG001 that has been shown to be safe and well-tolerated. No serious drug related adverse events have been reported. Only a few drug-related adverse events were reported as grades 1 or 2, and no pattern or dose relation was observed
The pharmacokinetic (PK) profile for FG001 was assessed for all dose levels. FG001 showed dose-dependent increases in exposure across dose levels in a linear manner.
Tumor-to-background ratio (TBR) is a measure of the contrast. At the optimal dose and time, 36 mg administered the evening before the surgery, all patients revealed a clinically relevant TBR value.
The histology samples from dose 36 mg, evening, and dose 48 mg, evening, have been unblinded and analyzed. The histology results confirm that FG001 lights up aggressive brain cancer.
Welcome by Morten Albrechtsen, CEO
Presentation by Principal Investigator, Chief surgeon Jane Skjøth-Rasmussen, MD, PhD
Future clinical trials in brain cancer by Morten Albrechtsen, CEO
Closing remarks by Morten Albrechtsen, CEO
Please register for this Webinar to view the dial-in info.
Morten Albrechtsen is an MD and BBA (‘HD’ in marketing, CBS). Morten is a seasoned entrepreneur with a strong medical, commercial and financial background. The expertise is gained within a broad range of therapeutic areas and with both drugs and...
Andreas Kjaer, is an MD, PhD, DMSc and professor at the University of Copenhagen and chief physician at Rigshospitalet, the National University Hospital of Denmark. His research is focused on molecular imaging with PET and PET/MRI in cancer and...
Chief Physician, Department of Neurosurgery , Rigshospitalet, and Associate Professor at University of Copenhagen
Jane Skjøth-Rasmussen is a neurosurgeon at Rigshospitalet, Copenhagen, Denmark. Subspecialized in paediatric neurosurgery, stereotactic surgery and neurooncology. Currently also employed at University of Copenhagen, Associate Professor (external),...